Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

TRVI holding history

Trevi Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

TRVI overviewAll 13F holders of TRVIFull Q2 2026 holdings

Shares (Q2 2026)
270,498
Value
$5.04M
% of portfolio
<0.1%
Quarters held
21
Since Q1 2021
Holdings of TRVI by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026270,498$5.04M<0.1%−175,694−39.4%ReducedHolders
Q1 2026446,192$5.32M<0.1%+171,564+62.5%AddedHolders
Q4 2025274,628$3.44M<0.1%−23,984−8.0%ReducedHolders
Q3 2025298,612$2.73M<0.1%−55,613−15.7%ReducedHolders
Q2 2025354,225$1.94M<0.1%+261,192+280.8%AddedHolders
Q1 202593,033$585.2K<0.1%+47,518+104.4%AddedHolders
Q4 202445,515$187.5K<0.1%+17,653+63.4%AddedHolders
Q3 202427,862$93.1K<0.1%+9,853+54.7%AddedHolders
Q2 202418,009$53.7K<0.1%−24,109−57.2%ReducedHolders
Q1 202442,118$145.3K<0.1%+10,741+34.2%AddedHolders
Q4 202331,377$42.0K<0.1%+8,802+39.0%AddedHolders
Q3 202322,575$49.2K<0.1%−1,480−6.2%ReducedHolders
Q2 202324,055$57.5K<0.1%+16,475+217.3%AddedHolders
Q1 20237,580$14.0K<0.1%+4,489+145.2%AddedHolders
Q4 20223,091$5.97K<0.1%−1,186−27.7%ReducedHolders
Q3 20224,277$7.00K<0.1%−494−10.4%ReducedHolders
Q2 20224,771$13.0K<0.1%+3,147+193.8%AddedHolders
Q1 20221,624$4.00K<0.1%+1,624NewHolders
Q4 20210$00.0%−5,173−100.0%Sold outHolders
Q3 20215,173$7.00K<0.1%+3,036+142.1%AddedHolders
Q2 20212,137$5.00K<0.1%−241−10.1%ReducedHolders
Q1 20212,378$6.00K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.